The Global Fund has revealed a groundbreaking initiative on Wednesday, collaborating with generic pharmaceutical manufacturers to significantly cut down the cost of an advanced HIV drug. This move, according to the organization, holds the potential to save numerous lives. Established in 2002 as a coalition to combat AIDS, tuberculosis, and malaria, the Global Fund stated that this new agreement will enable them to offer the state-of-the-art TLD medication for less than $45 per individual annually.
The reduction in price, amounting to 25%, is being celebrated as a pivotal development, allowing governments in economically constrained regions to expand the reach of vital HIV services. In a formal statement, the Global Fund emphasized the significance of this improved pricing in granting wider access to crucial services for managing HIV.
The medication in question, known as TLD, amalgamates three essential drugs: tenofovir disoproxil fumarate, lamivudine, and dolutegravir. Praised by the World Health Organization, this three-in-one pill has been recommended as the preferred primary treatment for HIV in adults and adolescents. It boasts the ability to rapidly suppress the AIDS-causing virus, while also being associated with fewer side effects and greater ease of consumption.
Peter Sands, the head of the Global Fund, underscored the financial challenges faced by countries most afflicted by HIV. He expressed that the price reduction for TLD is poised to unleash a positive domino effect, enabling governments and other entities supported by Global Fund grants to amplify treatment programs and allocate more resources to prevention efforts. Sands believes this could culminate in saving lives and reducing the number of new infections.
This pivotal announcement comes on the heels of a previous milestone achieved in 2017, wherein the Global Fund, in partnership with UNAIDS, the Bill & Melinda Gates Foundation, and other collaborators, secured licensing agreements that enabled TLD to be accessible in low- and middle-income nations for a price of up to $75 per person annually. At the time, this was a groundbreaking achievement in terms of affordability. Today, it is estimated that approximately 19 million more individuals living with HIV in resource-limited regions are benefiting from TLD, as highlighted by the Clinton Health Access Initiative.
Source: AFP
0 Comments